Metastatic Cervical Carcinoma with High-Risk Human Papillomavirus (HPV) Positive and P16/ Ki-67 Positive in a 28 Year-Old Female That Did Not Meet the Current Screening Guidelines
DOI:
https://doi.org/10.17140/GOROJ-2-111Keywords:
Cervical squamous cell carcinoma, Human papillomavirus, P16, Ki-67, Cervical screening guidelinesAbstract
A case presentation about an individual treated at Oklahoma State University Medical Center with high-grade metastatic squamous cell carcinoma of the cervix that was high-risk HPV and p16/Ki-67 positive. The clinical presentation, laboratory data, imaging, and subsequent therapy are reported as well as highlights of screening guidelines for cervical pathology.
References
Centers for Disease Control and Prevention. Press Release: More women getting Pap tests as recommended. http://www. cdc.gov/media/releases/2013/p0103_pap_test.html 2013; Ac-cessed April 6, 2015.
Centers for Disease Control and Prevention. Cervical cancer Screening Guidelines for Average-Risk Women. http://www.cdc. gov/cancer/cervical/pdf/guidelines.pdf 2012; Accessed April 6, 2015.
UpToDate. Screening for cervical cancer. http://www.uptodate. com/contents/screening-for-cervical-cancer?source=search_res ult&search=screening+for+cervical+cancer&selectedTitle=1% 7E150 2015; Accessed April 2, 2015.
Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cer-vical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013; 105: 1550. doi: 10.1093/jnci/djt235 Gynecol Obstet Res Open J Page 51
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Gynecology and Obstetrics Research (GOR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.